

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Henlius Biotech, Inc.

上海復宏漢霖生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 2696)

**(1) CHANGES IN NON-EXECUTIVE DIRECTOR AND
INDEPENDENT NON-EXECUTIVE DIRECTOR**

**(2) APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHANGES IN
COMPOSITION OF THE BOARD COMMITTEES**

**RESIGNATION OF NON-EXECUTIVE DIRECTOR AND INDEPENDENT
NON-EXECUTIVE DIRECTOR**

The board of directors (the “**Board**”) of Shanghai Henlius Biotech, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Mr. Wenjie Zhang has tendered his resignation as a non-executive Director and the Chairman of the Board of the Company, the member and chairman of the Nomination Committee, the member and chairman of the Strategy Committee and a member of the Environmental, Social and Governance Committee for his personal development reasons, with effect from 30 September 2026. Mr. Wenjie Zhang has confirmed that he has no disagreement with the Board and there are no other matters in respect of his resignation that need to be brought to the attention of the shareholders of the Company (the “**Shareholders**”).

The Board announces that Mr. Yihao Zhang has tendered his resignation as an independent non-executive Director and a member of the Nomination Committee of the Company for his personal development reasons, with effect from 30 September 2026. Mr. Yihao Zhang has confirmed that he has no disagreement with the Board and there are no other matters in respect of his resignation that need to be brought to the attention of the Shareholders.

The Board would like to take this opportunity to express its sincere gratitude to Mr. Wenjie Zhang and Mr. Yihao Zhang for their valuable contributions to the Company during their tenure of office.

**PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND INDEPENDENT
NON-EXECUTIVE DIRECTOR**

The Board is pleased to announce that Mr. Zhi Huang (“**Mr. Huang**”) and Dr. Huajun Chen (“**Dr. Chen**”) have been nominated as a non-executive Director and an independent non-executive Director of the fourth session of the Board, respectively, subject to the approval by the Shareholders at the general meeting.

The term of office of Mr. Huang as a non-executive Director shall commence from the date of approval by the Shareholders at the general meeting and end on the expiry of the term of the fourth session of the Board (or the term of office shall expire at the conclusion of the general meeting at which members of the next session of the Board will be elected). The Company will enter into a written service agreement with Mr. Huang upon the approval of his appointment as a non-executive Director of the Company at the general meeting. Mr. Huang will not receive any remuneration from the Company for acting as a non-executive Director of the Company. A circular of the general meeting containing details of the appointment will be despatched to the Shareholders in due course. For biographical details of Mr. Huang, please refer to the Appendix.

The term of office of Dr. Chen as an independent non-executive Director shall commence from the date of approval by the Shareholders at the general meeting and end on the expiry of the term of the fourth session of the Board (or the term of office shall expire at the conclusion of the general meeting at which members of the next session of the Board will be elected). The Company will enter into a written service agreement with Dr. Chen upon the approval of the appointment of Dr. Chen as an independent non-executive Director of the Company at the general meeting. Dr. Chen is entitled to a remuneration of HKD400,000 per annum (before tax) which was determined with reference to his experience, duties and responsibilities and the prevailing market rate of companies of comparable size and similar operations. A circular of the general meeting containing details of the appointment will be despatched to the Shareholders in due course. For biographical details of Dr. Chen, please refer to the Appendix.

APPOINTMENT OF CHAIRMAN OF THE BOARD AND CHANGES IN COMPOSITION OF THE BOARD COMMITTEES

The Board is pleased to announce that Dr. Xingli Wang (“**Dr. Wang**”) has been appointed as the chairman of the fourth session of the Board, the member and chairman of the Nomination Committee, the chairman of the Strategy Committee, and a member of the Environmental, Social and Governance Committee, with effect from 30 September 2026. The biographical details of Dr. Wang are set out in the Appendix.

The Board would like to take this opportunity to express its warmest welcome to Dr. Wang on his new appointment.

On behalf of the Board
Shanghai Henlius Biotech, Inc.
Xingli Wang
Chairman

Hong Kong, 30 September 2026

As at the date of this announcement, the board of directors of the Company comprises Dr. Xingli Wang as the chairman and non-executive director; Dr. Jun Zhu as executive director; Mr. Qiyu Chen, Mr. Yuqing Chen, Ms. Xiaohui Guan and Dr. Yi Liu as non-executive directors; and Mr. Tak Young So, Dr. Lik Yuen Chan and Dr. Ruilin Song as independent non-executive directors.

Appendix

The biographical details of Dr. Wang are set out below:

Dr. Xingli Wang, aged 63, has served as a non-executive Director of the Company since August 2023. Dr. Wang currently serves as the president and chief executive officer of the innovative medicine division of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“**Fosun Pharma**”, Shanghai Stock Exchange stock code: 600196, The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) stock code: 02196). He joined Fosun Pharma in January 2023, successively served as the executive president and co-president of Fosun Pharma, and has served as the president of Fosun Pharma since July 2026. In addition, Dr. Wang holds directorship in certain subsidiaries of Fosun Pharma.

Prior to joining Fosun Pharma and its subsidiaries (“**Fosun Pharma Group**”), Dr. Wang engaged in postdoctoral research in cardiovascular science at The University of New South Wales Australia (“**UNSW**”). He was successively engaged in clinical residency rotation at Prince of Wales Hospital in Sydney, and served as a senior lecturer in cardiovascular medicine at UNSW and a director of cardiothoracic surgery research and tenured professor at Baylor College of Medicine, USA. He served as a medical director of Schering-Plough Corporation (formerly listed on the New York Stock Exchange with stock code: SGP, merged into Merck & Co., Inc. in 2009). He worked in Novartis AG (New York Stock Exchange stock code: NVS), mainly serving as project director, global project clinical head, head of Novartis Global Drug R&D (China) and general manager of Biomedical Research Institute (China).

Dr. Wang obtained a bachelor’s degree in medicine from Shandong Medical College in China (merged into Shandong University in 2000) in July 1985 and a doctorate degree in cardiovascular science from UNSW in October 1991. Dr. Wang also holds a license to practice medicine in Australia.

The biographical details of Mr. Huang are set out below:

Mr. Huang, aged 55, joined Fosun Pharma in February 2026 and currently serves as senior vice president, chief financial officer and co-president of the innovative medicine division of Fosun Pharma.

Prior to joining Fosun Pharma Group, Mr. Huang was primarily engaged in finance-related work. From April 2007 to October 2020, he successively served at Novartis AG (New York Stock Exchange stock code: NVS) as business planning and analysis manager of the U.S. Oncology Business Unit, head of finance for western China, head of Business Processes and Controls for Greater China, head of Business Planning and Analysis for Greater China, and country chief financial officer for South Korea. From October 2020 to February 2025, he served as chief financial officer of Greater China, head of finance of APAC (ex-China), head of finance of the global technical operations, and head of finance of the innovation center at BeOne Medicines Ltd. (Shanghai Stock Exchange stock code: 688235; The Stock Exchange stock code: 06160; Nasdaq Stock Market stock code: ONC), during which period he served as head of finance of the Global Commercial of BeOne Medicines Ltd. from June 2023 to February 2025. From May 2025 to January 2026, he served as senior vice president of global corporate development & finance of Ascentage Pharma Group International (The Stock Exchange stock code: 06855; Nasdaq Stock Market stock code: AAPG).

Mr. Huang graduated from the Business School of Dowling College in the United States with a master's degree in banking and finance.

The biographical details of Dr. Chen are as follows:

Dr. Chen, aged 48, joined the College of Computer Science and Technology, Zhejiang University in December 2004, where he has successively served as a lecturer, associate professor and professor. Currently, he is a distinguished professor and doctoral supervisor at the College of Computer Science and Technology, Zhejiang University, where he is mainly engaged in research of artificial intelligence, knowledge graphs and natural language processing. Dr. Chen has been honored as a Young and Middle-aged Expert with Outstanding Contributions in Zhejiang Province, a Leading Talent in Science and Technology Innovation under the Special Support Program for High-level Talents in Zhejiang Province, and has been awarded the Second Prize of the Zhejiang Provincial Science and Technology Progress Award. Dr. Chen currently serves as vice president of the Zhejiang Digital Intelligence Technology Research Association, deputy director of the Language and Knowledge Computing Committee of the Chinese Information Processing Society of China, and vice chairman of the Digitalization Branch of China Information Association of Traditional Chinese Medicine.

Dr. Chen obtained his bachelor's degree in Bioengineering from Zhejiang University in June 2000, and his doctoral degree in Computer Science and Technology from Zhejiang University in March 2005.

Dr. Chen has confirmed that, as at the date of this announcement, (i) he has satisfied the various factors relating to independence as set out in Rules 3.13(1) to (8) of the Listing Rules; (ii) he has no past or present financial or other interest in the business of the Group or any connection with any core connected person (as defined under the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited ("**Listing Rules**")) of the Company; and (iii) there are no other factors that may affect his independence.

As at the date of this announcement, save as disclosed above, Dr. Wang, Mr. Huang and Dr. Chen have confirmed that they (i) did not hold any directorships or supervisor positions in any other listed companies in the past three years, nor take up any post in any members of the Group; (ii) did not have any relationship with any Directors, supervisors, senior management, substantial Shareholders or controlling Shareholders of the Company; and (iii) did not have any interests in the Shares or underlying Shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

Save as disclosed above, there is no other matter relating to the proposed appointment of non-executive Director and independent non-executive Director, appointment of Chairman of the Board and changes in composition of the Board committees that needs to be brought to the attention of the Shareholders, nor is there any other information required to be disclosed pursuant to any requirements of Rules 13.51(2)(h) to (v) of the Listing Rules.